Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells, a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors. A research team from Baylor College of Medicine has now published groundbreaking work in Nature Medicine investigating Multi-Antigen Targeted T cells in patients with pancreatic cancer. The Phase 1/2 clinical study conducted at Baylor College of Medicine demonstrated encouraging objective clinical responses and a disease control rate of 84.6% when combining Multi-Antigen Targeted T cells with frontline chemotherapy. In this arm of the study, median duration of response for patients achieving a partial or complete response was 7.5 months with a median overall survival rate of 14.1 months suggesting a clinical benefit of combining Multi-Antigen Targeted T cells with standard chemotherapy. Clinical results from this Phase 1 study demonstrated a favorable safety profile and potential synergistic effect when combining Multi-Antigen Targeted T cells with chemotherapy without affecting the toxicity profile. Chemotherapy was previously shown to break down the tumor’s supporting stromal cells, which act as a protective barrier, to facilitate T cell infiltration into the tumor and to boost anti-tumor response. The research group from Baylor also highlighted a correlation between the clinical effect and the expansion and persistence of infused Multi-Antigen Targeted T cells. The data showed that infused T cells were still present in patients 12 months post-treatment and found at higher frequencies in patients that responded to the investigational product.